Oracle Rolls Out AI Agents for Clinical Trials, Humans Keep the Final Say
Oracle is putting AI agents inside clinical trial operations. The Life Sciences AI Agents went out to early adopters on November 18, 2026, flagging problems and drafting fixes while humans keep the final say on anything that actually runs.
- Original source: unite.ai.
- The source published it on Nov 18, 2026 at 5:20 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Oracle Life Sciences AI Agents are now in the hands of early adopters as of November 18, 2026, forming an AI-assisted coordination layer for clinical trial operations. The opening beat is deliberately tight: portfolio monitoring, trial planning and trial conduct. Every proposed action lands in front of a human for review and approval before it executes.
The agents gather insights from Oracle Life Sciences applications plus supported third-party data sources. From there they identify operational issues, recommend actions and coordinate the response across studies, applications, data and teams. One example Oracle gives: an agent watches study performance and the likely drivers behind swings in key performance indicators, then proposes operational actions that stay inside the trial protocol.
Seema Verma, executive vice president and general manager of Oracle Health and Life Sciences, said the aim is to “monitor performance, identify emerging risks, and coordinate responses across the trial lifecycle.” The offering bundles Oracle's Life Sciences applications with AI-assisted capabilities, connected data services and cloud infrastructure.
The agents slot into an existing portfolio that already covers portfolio planning, study startup, electronic trial master file management and clinical trial management, all running through Oracle Cloud Infrastructure. Oracle Life Sciences CTMS centrally tracks study activities, site performance and regulatory documentation, while interoperability with electronic data capture and eTMF systems underpins data integrity and oversight across a research portfolio.
Oracle plans to extend the agentic capabilities into clinical data management, post-trial analytics, trial design and post-market workflows. Those are roadmap items, not part of the early-adopter release. The wider Life Sciences platform serves sponsors, contract research organizations and research sites, spanning clinical trial data collection, pharmacovigilance and data intelligence, with embedded AI and analytics supporting study design and execution.
TopicsOracle · Oracle Life Sciences AI Agents · Seema Verma · Oracle Health and Life Sciences · Oracle Life Sciences CTMS · Oracle Cloud Infrastructure
Source: unite.ai
Written by AI from verified reporting.
More stories
- Tech & AI x.com 0 viewsNvidia Erases Entire Post-Earnings Rally, Turns Red Despite Beat
- Tech & AI x.com 0 viewsBezos Warns Nvidia an Outside CEO Hire Would Almost Certainly Fail
- Tech & AI x.com 0 viewsCambridge Dictionary crowns 'human' its 2026 word of the year
- Tech & AI x.com 2 sources 0 viewsNvidia's Brutal Week Split Its Seven Tokenized Shares on Price

